(Q42513261)

English

Treatment of Basal Cell Carcinoma Located in the Head and Neck Region with Intralesional Interferon alpha-2a : Evaluation of Long-Term Follow-Up Results

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Treatment of Basal Cell Carcinoma Located in the Head and Neck Region with Intralesional Interferon alpha-2a : Evaluation of Long-Term Follow-Up Results (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

author name string

Seher Bostanci

1

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Pelin Kocyigit

2

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Ayşegül Alp

3

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Cengizhan Erdem

4

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Erbak Gürgey

5

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Clinical Drug Investigation

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

661-667

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

A critical function for type I interferons in cancer immunoediting

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of basal cell carcinoma with intralesional interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The alpha interferons: clinical overview.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha in tumor immunity and immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of large basal-cell carcinomas with intralesional interferon-alpha-2a

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biology of basal cell carcinoma (Part I).

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intralesional alpha 2b recombinant interferon for basal cell carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of basal cell carcinoma with intralesional interferon alpha-2a.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intralesional interferon-alpha 2b treatment of basal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of neoplastic skin lesions with intralesional interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor actions of interferons. Direct, indirect, and synergy with other treatment modalities

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Principles of management of basal and squamous cell carcinoma of the skin

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regional and intralesional treatment of invasive basal cell carcinoma with interferon alfa-n2b

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of basal cell carcinoma with intralesional interferon alpha-2b

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonsurgical management of primary skin malignancies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intralesional interferon in basal cell carcinoma: how does it work?

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intralesional alfa-2a interferon therapy for basal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential of interferon-alpha in solid tumours: part 1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mohs surgery. Technique, indications, applications, and the future

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adequate follow-up for treated basal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intralesional interferon therapy for basal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of aggressive basal cell carcinoma with intralesional interferon: Evaluation of efficacy by Mohs surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17532711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00044011-200525100-00005

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42513261&oldid=1960240050"